{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:07:27Z","timestamp":1791317247310,"version":"4.3.1"},"reference-count":22,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2021.44386","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T16:06:57Z","timestamp":1642694817000},"page":"e2144386","source":"Crossref","is-referenced-by-count":15,"title":["Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use"],"prefix":"10.1001","volume":"5","author":[{"given":"Ameet","family":"Sarpatwari","sequence":"first","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice L.","family":"Brown","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah A.","family":"McGraw","sequence":"additional","affiliation":[{"name":"The Hastings Center, Garrison, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Z.","family":"Dejene","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman","family":"Abdurrob","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian J.","family":"Santiago Ortiz","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Kesselheim","sequence":"additional","affiliation":[{"name":"Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,1,20]]},"reference":[{"issue":"12","key":"zoi211230r1","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1056\/NEJMp1803910","article-title":"The FDA Amendments Act of 2007\u2013assessing its effects a decade later.","volume":"379","author":"Avorn","year":"2018","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi211230r3","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1056\/NEJMp1400488","article-title":"Using a drug-safety tool to prevent competition.","volume":"370","author":"Sarpatwari","year":"2014","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi211230r5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40264-021-01070-2","article-title":"Methodological approaches to evaluate the impact of risk evaluation and mitigation strategy (REMS) programs.","volume":"44","author":"Sarpatwari","year":"2021","journal-title":"Drug Saf"},{"issue":"2","key":"zoi211230r7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/cpt.17","article-title":"Are risk evaluation and mitigation strategies associated with less off-label use of medications: the case of immune thrombocytopenia.","volume":"97","author":"Sarpatwari","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"zoi211230r8","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jama.2019.0235","article-title":"Assessment of the FDA risk evaluation and mitigation strategy for transmucosal immediate-release fentanyl products.","volume":"321","author":"Rollman","year":"2019","journal-title":"JAMA"},{"key":"zoi211230r9","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212272","article-title":"Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function.","volume":"4","author":"Blanchette","year":"2015","journal-title":"Drugs Context"},{"issue":"3","key":"zoi211230r10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.1340","article-title":"Association of a risk evaluation and mitigation strategy program with transmucosal fentanyl prescribing.","volume":"2","author":"Fleischman","year":"2019","journal-title":"JAMA Netw Open."},{"issue":"3","key":"zoi211230r11","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s40264-020-01017-z","article-title":"Changes in erythropoiesis stimulating agent use under a risk evaluation and mitigation strategy (REMS) program.","volume":"44","author":"Sarpatwari","year":"2021","journal-title":"Drug Saf"},{"issue":"4","key":"zoi211230r12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40264-016-0501-2","article-title":"Effectiveness of risk evaluation and mitigation strategies (REMS) for lenalidomide and thalidomide: patient comprehension and knowledge retention.","volume":"40","author":"Brandenburg","year":"2017","journal-title":"Drug Saf"},{"issue":"9","key":"zoi211230r13","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/pds.v27.9","article-title":"What is the quality of drug safety information for patients: An analysis of REMS educational materials.","volume":"27","author":"Chan","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"zoi211230r14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","article-title":"Three approaches to qualitative content analysis.","volume":"15","author":"Hsieh","year":"2005","journal-title":"Qual Health Res"},{"issue":"32","key":"zoi211230r15","first-page":"1","article-title":"Reducing confusion about grounded theory and qualitative content analysis: similarities and differences.","volume":"19","author":"Cho","year":"2014","journal-title":"Qualitative Rep"},{"issue":"10","key":"zoi211230r16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1161\/CIRCULATIONAHA.107.742775","article-title":"Qualitative and mixed methods provide unique contributions to outcomes research.","volume":"119","author":"Curry","year":"2009","journal-title":"Circulation"},{"issue":"3","key":"zoi211230r19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.pec.2014.05.027","article-title":"Development of the Patient Education Materials Assessment Tool (PEMAT): a new measure of understandability and actionability for print and audiovisual patient information.","volume":"96","author":"Shoemaker","year":"2014","journal-title":"Patient Educ Couns"},{"issue":"2","key":"zoi211230r20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.2307\/3562038","article-title":"False hopes and best data: consent to research and the therapeutic misconception.","volume":"17","author":"Appelbaum","year":"1987","journal-title":"Hastings Cent Rep"},{"issue":"7","key":"zoi211230r21","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1001\/jama.2019.0236","article-title":"Mitigating health risks of prescription drugs: lessons from FDA oversight of opioid products.","volume":"321","author":"Sarpatwari","year":"2019","journal-title":"JAMA"},{"key":"zoi211230r2"},{"key":"zoi211230r4","unstructured":"US Food and Drug Administration. Approved risk evaluation and mitigation strategies (REMS). Accessed November 18, 2021. https:\/\/www.accessdata.fda.gov\/scripts\/cder\/rems\/index.cfm"},{"key":"zoi211230r6","unstructured":"US Government Accountability Office. FDA lacks comprehensive data to determine whether risk evaluation and mitigation strategies improve drug safety. Published February 12, 2013. Accessed August 9, 2021. https:\/\/oig.hhs.gov\/oei\/reports\/OEI-04-11-00510.asp"},{"key":"zoi211230r17","unstructured":"Lundbeck. U.S. FDA approves changes to the Sabril (vigabatrin) REMS program. Published June 24, 2016. Accessed November 18, 2021. https:\/\/www.biospace.com\/article\/releases\/lundbeck-inc-release-fda-approves-changes-to-the-sabril-vigabatrin-rems-program-\/"},{"key":"zoi211230r18","unstructured":"United States Food and Drug Administration. FDA-approved labeling 8\/21\/09. Published August 21, 2009. Accessed November 18, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/020427s000lbl.pdf"},{"key":"zoi211230r22","unstructured":"UBC. The topic questions to ask when developing a REMS. Accessed November 18, 2021. https:\/\/ubc.com\/the-top-5-questions-to-ask-when-developing-a-rems\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2788241\/sarpatwari_2022_oi_211230_1642007433.33433.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T16:07:09Z","timestamp":1642694829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2788241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,20]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44386","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,20]]}}}